Standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever
Brighton Collaboration Releases New Template for Evaluating VSV-Based Lassa Fever Vaccines The Brighton Collaboration is proud to announce the publication of a new standardized template to support benefit-risk assessments for vesicular stomatitis virus (VSV) vector vaccines targeting Lassa fever. This tool is designed to enhance scientific consistency, transparency, and rigor in evaluating novel vaccine platforms. 🔗 Read the full article: ScienceDirect – Vaccine Journal Lassa fever is an emerging infectious disease with increasing public health significance, particularly in West Africa.